Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by canadapieton Feb 25, 2020 10:30am

84 Views

Post# 30730468

RE:RE:Phase 3 NASH & no cash burn in 2020

Well, mr. T. said it too, the share price is ridiculously low!!! And so becoming
cheaper...., and cheaper!!!!
Who wants such a "dog" in his portfolio???

So we have to wait for another year and in the meantime missing lots
of possibilities!
But what he said on the phone was the truth, so will give him again
the benifit of the doubt !

jfm1330 - (2/25/2020 10:14:22 AM)
RE:Phase 3 NASH & no cash burn in 2020

So a lot of overanalysis here in the last few months. After listening to the call, it seems that everything is going relatively well. 14% growth from Q3 to Q4 for Trogarzo, which is very good under the lowered expectations for this drug. It will take longer with the FDA but their goal is still to launch a phase III trial in NAFLD/NASH at the begining of 2021. They seem very enthusiastic about the oncology program. They said they will present some new data at cancer conferences during 2020. They are aware of results that we don't know. So this enthusiatic tone bodes well. Finally the hired their IR person and they said that this person had a long background with a big US biotech company. So all those focusing on promoting the stock should be happy. So all in all, I think it goes relatively well and the the actual SP is just unwarranted

Bullboard Posts

First Nations contributions attract investor interest